Diabetes mellitus and stroke: A clinical update

Table 5 Trials of statin therapy with individual participant data and relative reduction of cardiovascular event rate including stroke

Study	Randomized participants, age	Type of Prevention	Diabetes participants (%)	Intervention (mg/d)	Follow-up (yr)	Relative reduction of CVE rate
4S[92,93]	4444, 35-70 years old	Secondary	202 (4.50%)	S20-40	5.4	37%
CARE[94,95]	4159, 21-75 years old	Secondary	586 (14.10%)	P40	5.0	25%
LIPID[91,96]	9014, 31-75 years old	Secondary	1077 (11.9%)	P40	6.1	21%
ALLHAT-LLT[97]	10355, ≥ 55 years old	Primary	3638 (35%)	P40	4.8	11%
HSPC[89]	20536, 40-80 years old	Primary, secondary	5963 (29%)	S40	4.8	22% total 33% primary
ASCOT-LLA[98,99]	19342, 40-79 years old	Primary	2532 (13%)	A10	3.3	23%
CARDS[90]	2838, 40-75 years old	Primary	2838 (100%)	A10	3.9	37%

CVE: Cardiovascular event; S: Simvastatin; P: Pravastatin; A: Atorvastatin.